[
  {
    "ts": "2025-09-23T21:00:00+00:00",
    "headline": "Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones",
    "summary": "TORONTO, September 23, 2025--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (\"Cybin\" or the \"Company\"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today highlights significant clinical and regulatory milestones and upcoming value-driving catalysts as the Company advances multiple programs towards potential commercialization.",
    "url": "https://finance.yahoo.com/news/cybin-highlights-neuropsychiatry-platform-upcoming-210000484.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "ca59d5d6-4ec6-36cc-89b5-2de65dd92641",
      "content": {
        "id": "ca59d5d6-4ec6-36cc-89b5-2de65dd92641",
        "contentType": "STORY",
        "title": "Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones",
        "description": "",
        "summary": "TORONTO, September 23, 2025--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (\"Cybin\" or the \"Company\"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today highlights significant clinical and regulatory milestones and upcoming value-driving catalysts as the Company advances multiple programs towards potential commercialization.",
        "pubDate": "2025-09-23T21:00:00Z",
        "displayTime": "2025-09-23T21:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/c3be583d0d5413268a17f927eab96d9b",
          "originalWidth": 460,
          "originalHeight": 268,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m7I3st7y_J9tcMUhaeIt2A--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c3be583d0d5413268a17f927eab96d9b.cf.webp",
              "width": 460,
              "height": 268,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cVa7aCCS17YSQiq2GJcL.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c3be583d0d5413268a17f927eab96d9b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cybin-highlights-neuropsychiatry-platform-upcoming-210000484.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cybin-highlights-neuropsychiatry-platform-upcoming-210000484.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CYBN"
            },
            {
              "symbol": "CBOE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]